{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:52:23Z","timestamp":1740135143820,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Vaccination is the most effective method to prevent the spread of infectious diseases and helps reduce mortality rate and economic costs associated with the pandemic. Despite these advantages, misinformation on vaccine safety and efficacy can lead to increased hesitation towards vaccination. This study reports the incidence of adverse events following Covishield vaccination, their associated factors, medication used for their management, and attitudes about vaccine safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional study was conducted from the sample of Covishield-vaccinated individuals from a secondary hospital, two primary health centres, and 36 health posts in eastern Nepal. Individuals (<jats:italic>n<\/jats:italic>\u2009=\u2009602) were randomly sampled from a population (<jats:italic>n<\/jats:italic>\u2009=\u20091013) who had received the first dose of Covishield, namely frontline workers and other high-risk populations. The second-round follow-up had 516 participants. Association of incidence and severity of post-vaccination events with socio-demographic variables, comorbidity status, and medication use were estimated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 79.9% of participants who reported adverse events after receiving the first dose, two-thirds of complaints were mild (67.4%, 95% CI 63.2\u201371.6) with the most common complaint being pain at the injection site (86.5%). Paracetamol or its combination with NSAIDs were used in the majority of cases (95.2%). After the second dose, only 31.2% (95% CI 27.2\u201335.2) reported adverse events, the overwhelming majority of which were mild (95.7%) and required a lower frequency of medication (7.5% vs. 26.0%). Adverse event following immunization were significantly associated with being 18\u201330\u00a0years old (\u03c7<jats:sup>2<\/jats:sup>\u2009=\u200916.9, <jats:italic>df<\/jats:italic>\u2009=\u20093, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and female gender (\u03c7<jats:sup>2<\/jats:sup>\u2009=\u20095.2, <jats:italic>df<\/jats:italic>\u2009=\u20091, p\u2009&lt;\u20090.05). Prior to the first dose, 86.0% of participants (95% CI 83.3\u201388.8%) perceived the vaccine to be safe, and 96.0% recommended the vaccine post-vaccination, while 96.8% were interested in receiving the second dose. AEFI severity was negatively associated with vaccine recommendation to the peers (odds-ratio 0.062, p\u2009&lt;\u20090.05) following the first dose, whereas, the optimistic pre-vaccination perception was associated with positive vaccine recommendation post-vaccination (odds-ratio 28.658, p\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Overall, vaccination-associated events were mild and majority were managed with paracetamol or its combination. Effective counselling about adverse events before vaccination should be prioritized to reduce hesitation and fear.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07406-2","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T12:03:12Z","timestamp":1651579392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Determinants of associated events following AZD1222 (Covishield) vaccination in a high-risk population in Nepal"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6749-7435","authenticated-orcid":false,"given":"Kapil Madi","family":"Poudel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4615-9901","authenticated-orcid":false,"given":"Neha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9958-2981","authenticated-orcid":false,"given":"Manab","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9056-2140","authenticated-orcid":false,"given":"Santosh Kumar","family":"Deo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2182-8862","authenticated-orcid":false,"given":"Sunita","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9869-022X","authenticated-orcid":false,"given":"Tika Ram","family":"Poudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"issue":"02","key":"7406_CR1","first-page":"830","volume":"4","author":"L Das","year":"2021","unstructured":"Das L, Meghana A, Paul P, Ghosh S. Are we ready for Covid\u201319 vaccines?\u2014a general side effects overview. J Curr Med Res Opin. 2021;4(02):830\u201341.","journal-title":"J Curr Med Res Opin."},{"key":"7406_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10926-021-09958-7","author":"D Griffiths","year":"2021","unstructured":"Griffiths D, Sheehan L, van Vreden C, Petrie D, Grant G, Whiteford P, et al. The impact of work loss on mental and physical health during the COVID-19 pandemic: baseline findings from a prospective cohort study. J Occup Rehabil. 2021. https:\/\/doi.org\/10.1007\/s10926-021-09958-7.","journal-title":"J Occup Rehabil"},{"issue":"12","key":"7406_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243693","volume":"15","author":"DJ Miller","year":"2020","unstructured":"Miller DJ, Capodilupo JV, Lastella M, Sargent C, Roach GD, Lee VH, et al. Analyzing changes in respiratory rate to predict the risk of COVID-19 infection. PLoS ONE. 2020;15(12): e0243693.","journal-title":"PLoS ONE"},{"issue":"11","key":"7406_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241536","volume":"15","author":"M Yanes-Lane","year":"2020","unstructured":"Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: a systematic review and meta-analysis. PLoS ONE. 2020;15(11): e0241536.","journal-title":"PLoS ONE"},{"issue":"4","key":"7406_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41562-021-01079-8","volume":"5","author":"T Hale","year":"2021","unstructured":"Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nat Hum Behav. 2021;5(4):529\u201338.","journal-title":"Nat Hum Behav"},{"issue":"51","key":"7406_CR6","doi-asserted-by":"publisher","first-page":"22020","DOI":"10.1073\/pnas.1009094108","volume":"107","author":"M Salathe","year":"2010","unstructured":"Salathe M, Kazandjieva M, Lee JW, Levis P, Feldman MW, Jones JH. A high-resolution human contact network for infectious disease transmission. Proc Natl Acad Sci USA. 2010;107(51):22020\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"7406_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/vaccines9040349","volume":"9","author":"Y Yan","year":"2021","unstructured":"Yan Y, Pang Y, Lyu Z, Wang R, Wu X, You C, et al. The COVID-19 vaccines: recent development, challenges and prospects. Vaccines. 2021;9(4):349.","journal-title":"Vaccines"},{"issue":"3\u20134","key":"7406_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/XEB.0000000000000077","volume":"14","author":"PK Strohfus","year":"2016","unstructured":"Strohfus PK, Brown SR, Potratz P. Effective and sustainable advice line promotes safe vaccine practices. Int J Evid Based Healthc. 2016;14(3\u20134):130\u20135.","journal-title":"Int J Evid Based Healthc"},{"key":"7406_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1926183","author":"K Dhama","year":"2021","unstructured":"Dhama K, Sharun K, Tiwari R, Dhawan M, Emran TB, Rabaan AA, et al. COVID-19 vaccine hesitancy\u2013reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic. Hum Vaccines Immunother. 2021. https:\/\/doi.org\/10.1080\/21645515.2021.1926183.","journal-title":"Hum Vaccines Immunother"},{"issue":"10","key":"7406_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-004206","volume":"5","author":"SL Wilson","year":"2020","unstructured":"Wilson SL, Wiysonge C. Social media and vaccine hesitancy. BMJ Glob Health. 2020;5(10): e004206.","journal-title":"BMJ Glob Health"},{"issue":"6","key":"7406_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/jech.54.6.402","volume":"54","author":"T Jefferson","year":"2000","unstructured":"Jefferson T. Real or perceived adverse effects of vaccines and the media\u2014a tale of our times. J Epidemiol Commun Health. 2000;54(6):402\u20133.","journal-title":"J Epidemiol Commun Health."},{"issue":"3","key":"7406_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000069172","volume":"49","author":"A Banzhoff","year":"2003","unstructured":"Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology. 2003;49(3):177\u201384.","journal-title":"Gerontology"},{"issue":"13","key":"7406_CR13","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1016\/j.vaccine.2011.01.071","volume":"29","author":"KL Flanagan","year":"2011","unstructured":"Flanagan KL, Klein SL, Skakkebaek NE, Marriott I, Marchant A, Selin L, et al. Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine. 2011;29(13):2349\u201354.","journal-title":"Vaccine"},{"issue":"3","key":"7406_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/acel.12326","volume":"14","author":"C Giefing-Kroll","year":"2015","unstructured":"Giefing-Kroll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015;14(3):309\u201321.","journal-title":"Aging Cell"},{"issue":"3","key":"7406_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/tbm\/ibaa147","volume":"11","author":"JL Saleska","year":"2021","unstructured":"Saleska JL, Choi KR. A behavioral economics perspective on the COVID-19 vaccine amid public mistrust. Transl Behav Med. 2021;11(3):821\u20135.","journal-title":"Transl Behav Med"},{"issue":"4","key":"7406_CR16","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3201\/eid2704.210016","volume":"27","author":"S Amit","year":"2021","unstructured":"Amit S, Beni SA, Biber A, Grinberg A, Leshem E, Regev-Yochay G. Postvaccination COVID-19 among Healthcare Workers, Israel. Emerg Infect Dis. 2021;27(4):1220.","journal-title":"Emerg Infect Dis"},{"key":"7406_CR17","unstructured":"Joshi U, Singh P. Adverse reaction following COVISHEILD a covid 19 vaccine-experience of from a single centre. 2021."},{"issue":"3","key":"7406_CR18","first-page":"1663","volume":"25","author":"S Meo","year":"2021","unstructured":"Meo S, Bukhari I, Akram J, Meo A, Klonoff D. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"7406_CR19","first-page":"168","volume-title":"Tables for statisticians","author":"H Arkin","year":"1963","unstructured":"Arkin H, Colton RR. Tables for statisticians. New York: Barnes and Noble. Inc; 1963. p. 168."},{"key":"7406_CR20","doi-asserted-by":"crossref","unstructured":"Jayadevan R, Shenoy RS, Anithadevi T. Survey of symptoms following COVID-19 vaccination in India. medRxiv. 2021.","DOI":"10.1101\/2021.02.08.21251366"},{"key":"7406_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2021.101989","author":"R Sah","year":"2021","unstructured":"Sah R, Shrestha S, Mehta R, Sah SK, Raaban AR, Dharma K, et al. AZD1222 (Covishield) vaccination for COVID-19: experiences, challenges and solutions in Nepal. Travel Med Infect Dis. 2021. https:\/\/doi.org\/10.1016\/j.tmaid.2021.101989.","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"7406_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3126\/jpahs.v8i1.36242","volume":"8","author":"S Shrestha","year":"2021","unstructured":"Shrestha S, Devbhandari RP, Shrestha A, Aryal S, Rajbhandari P, Shakya B, et al. Adverse events following the first dose of ChAdOx1 nCoV-19 (COVISHIELD) vaccine in the first phase of vaccine roll out in Nepal. J Patan Acad Health Sci. 2021;8(1):9\u201317.","journal-title":"J Patan Acad Health Sci"},{"key":"7406_CR23","unstructured":"R-CoreTeam. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2020."},{"key":"7406_CR24","doi-asserted-by":"crossref","unstructured":"Krammer F, Srivastava K, Simon V. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. medRxiv. 2021.","DOI":"10.1101\/2021.01.29.21250653"},{"key":"7406_CR25","doi-asserted-by":"publisher","first-page":"100517","DOI":"10.1016\/j.waojou.2021.100517","volume":"14","author":"PJ Turner","year":"2021","unstructured":"Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, Yehia E-G, et al. COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14:100517.","journal-title":"World Allergy Organ J"},{"issue":"10267","key":"7406_CR26","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2020","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet. 2020;396(10267):1979\u201393.","journal-title":"Lancet"},{"issue":"1","key":"7406_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-018-0094-0","volume":"4","author":"T Potluri","year":"2019","unstructured":"Potluri T, Fink AL, Sylvia KE, Dhakal S, Vermillion MS, Vom Steeg L, et al. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. NPJ Vaccines. 2019;4(1):1\u201312.","journal-title":"NPJ Vaccines"},{"issue":"8","key":"7406_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","volume":"70","author":"J Gee","year":"2021","unstructured":"Gee J. First month of COVID-19 vaccine safety monitoring\u2014United States, December 14, 2020\u2013January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(8):283\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"7406_CR29","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1001\/jama.2021.3976","volume":"325","author":"KG Blumenthal","year":"2021","unstructured":"Blumenthal KG, Robinson LB, Camargo CA, Shenoy ES, Banerji A, Landman AB, et al. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021;325(15):1562\u20135.","journal-title":"JAMA"},{"key":"7406_CR30","doi-asserted-by":"crossref","unstructured":"Remlabeevi A, Mathew T, Nair H, Nair GLR, Alex MR. Adverse events and their association with comorbidities after first and second doses of Covishield vaccination among healthcare workers of Government owned medical colleges in Kerala. medRxiv. 2021.","DOI":"10.1101\/2021.05.19.21257317"},{"issue":"2","key":"7406_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.52403\/gijhsr.20210408","volume":"6","author":"SB Shah","year":"2021","unstructured":"Shah SB, Chawla R, Mehta A. SARS-CoV-2: comparison of active immunity acquired by natural exposure versus inoculation of HCW. Galore Int J Health Sci Res. 2021;6(2):54\u201363.","journal-title":"Galore Int J Health Sci Res"},{"key":"7406_CR32","unstructured":"GoN\/CBS. Report on the Nepal Labour Force Survey 2017\/2018. 2019."},{"issue":"8","key":"7406_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134834","volume":"10","author":"KK Aryal","year":"2015","unstructured":"Aryal KK, Mehata S, Neupane S, Vaidya A, Dhimal M, Dhakal P, et al. The burden and determinants of non communicable diseases risk factors in Nepal: findings from a nationwide STEPS survey. PLoS ONE. 2015;10(8): e0134834.","journal-title":"PLoS ONE"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07406-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07406-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07406-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T12:04:46Z","timestamp":1651579486000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07406-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7406"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07406-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"11 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Nepal Health Research Council (ERB Protocol Registration No. 325\/2021 P) after the submission of a brief research proposal, which was subjected to double-blind review and certified to fulfil the required protocol. All methods were performed in accordance with the relevant guidelines and regulations of NHRC. Informed consent was obtained from all the participants. Data generation was done after surveyors explicitly got both verbal and written consent from survey participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interests exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"422"}}